0001209191-21-026394.txt : 20210412 0001209191-21-026394.hdr.sgml : 20210412 20210412203355 ACCESSION NUMBER: 0001209191-21-026394 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210408 FILED AS OF DATE: 20210412 DATE AS OF CHANGE: 20210412 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loven Jakob CENTRAL INDEX KEY: 0001753644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39592 FILM NUMBER: 21821796 MAIL ADDRESS: STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK STREET 2: 395 WINCHESTER AVENUE CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kronos Bio, Inc. CENTRAL INDEX KEY: 0001741830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: 212-871-7920 MAIL ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-08 0 0001741830 Kronos Bio, Inc. KRON 0001753644 Loven Jakob C/O KRONOS BIO, INC. 1300 SO. EL CAMINO REAL, SUITE 300 SAN MATEO CA 94402 1 0 0 0 Common Stock 2021-04-08 4 S 0 38312 27.09 D 1507032 I See footnote Common Stock 2021-04-08 4 S 0 24816 27.91 D 1482216 I See footnote Common Stock 2021-04-09 4 S 0 21660 27.20 D 1460556 I See footnote Common Stock 2021-04-12 4 S 0 15728 26.27 D 1444828 I See footnote Common Stock 2021-04-12 4 S 0 100 27.21 D 1444728 I See footnote Shares were sold pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.47 to $28.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $27.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Darren DeStefano, Attorney-in-Fact 2021-04-12 EX-24.4_978896 2 poa.txt POA DOCUMENT POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Catherine Rude and Darren DeStefano of Cooley LLP, signing individually, the undersigned's true and lawful attorney-in-fact and agent to: (1) Prepare and execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder relating to securities of any company in which any entity associated with the undersigned beneficially owns, or has at any time beneficially owned, any equity interest (a "Portfolio Company"), and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder relating to any Portfolio Company; and (2) Take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of undersigned, are not assuming, nor is Cooley LLP assuming, any of the undersigned's responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned's holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be associated with Cooley LLP (or its successor), as applicable. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below: Date: April 12, 2021 /s/ Jakob Loven